

RECEIVED

SEP 22 2005

TECH CENTER 1600/2900

PATENT
0230-0145P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: NAKAMURA Seiji et al.
Appl. No.: Rule 53(b) of Application Group: UNKNOWN
 No. 08/669,286
Filed: December 22, 1999 Examiner: UNKNOWN
For: GENE ENCODING ADSEVERIN

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION WITH CONTINUATION-IN-PART OR
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Assistant Commissioner for Patents
Washington, DC 20231

December 22, 1999

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicants hereby submit an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form, attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form is requested since any patents, publications, or other information which are listed on the PTO-1449 form but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No.

08/669,286

U.S. Filing Date

June 28, 1996

III. FEES


This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Gerald M. Murphy, Jr., #28,977

MaryAnne Armstrong, #40,069

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

¹⁴
GMM/MAA/mar
0230-0145P

Enclosures: ☒ PTO-1449
☒ References
☐ Foreign Search Report
☐ Other:

(Rev. 03/30/99)

Form PTO-1449

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

ATTY DOCKET NO.
0230-0145PAPPLICATION NO.
NewAPPLICANT
NAKAMURA Seiji et al.FILING DATE
December 22, 1999GROUP
UNKNOWN**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION
					YES NO
WO 91 15 7 7 0 A	1991-10-17	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	Database EMBL, Entry MM04354, Accession No. U04354, December 17, 1993.
	A. Rodriguez, et al., <i>The EMBO Journal</i> , Vol. 9, No. 1, pages 43-52, (1990).
	L. Tchakarov, et al., <i>FEBS Letters</i> , Vol. 268, No. 1, pages 209-212 (1990).
	M. G. Marcu, et al. <i>Molecular and Cellular Biochemistry</i> , Vol. 141, No. 2, pages 153-165, (1994).
	P. A. Janmey, et al., <i>Blood</i> , Vol. 80, No. 4, pages 928-936, (1992).
	Berendsen. <i>Science</i> , Vol. 282, pages 642-643, (October 1998).
	S. Nakamura, et al. <i>J. of Biological Chemistry</i> , Vol. 8, No. 269, pages 5890-5896, (1994).
	S. Nakamura, et al. <i>Jpn. J. Pharmacol.</i> , Vol. 61, Suppl.1, page 294, (1993).
	T. Sakurai, et al. <i>J. of Biological Chemistry</i> , Vol. 266, No. 24, pages 15979-15983, (1991).
	T. Sakurai, et al. <i>Journal of Biological Chemistry</i> , Vol. 266, No. 7, pages 4581-4585, (1991).
	T. Sakurai, et al. <i>Neuroscience</i> , Vol. 38, No. 3, pages 743-756, (1990).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

GMM/MAL/mar